Global Beta-Lactam and Beta-Lactamase Inhibitors Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Beta-Lactam and Beta-Lactamase Inhibitors Market was valued at $30.5 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 3.8% CAGR, to an estimated market size of $36.8 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The market encompasses beta-lactam antibiotics (including penicillins, cephalosporins, carbapenems, and monobactams) and beta-lactamase inhibitors co-administered to treat bacterial infections. The scope focuses on therapies that target bacterial cell wall synthesis while utilizing inhibitors to neutralize enzymes that cause antimicrobial resistance (AMR), primarily in hospital and critical care settings.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Beta-Lactam and Beta-Lactamase Inhibitors Market in the period 2025-30:
- The escalating prevalence of antimicrobial resistance (AMR) is the primary driver, forcing a shift toward novel inhibitor combinations to maintain treatment efficacy.
- There is a structural move toward precision-guided therapy supported by rapid microbiology and molecular diagnostics to reduce broad-spectrum empiric prescribing.
- Integration of Artificial Intelligence (AI) is accelerating drug discovery and clinical decision support for predicting patient risk and susceptibility patterns.
- Regulatory bodies are providing incentives and priority pathways for new antibiotics targeting resistant Gram-negative pathogens like carbapenemases.
- Manufacturers are increasingly focusing on supply chain resilience and API backward integration to mitigate global shortages of essential injectable antibiotics.
- Rising healthcare expenditure and expanded access to essential medicines in Low- and Middle-Income Countries (LMICs) are creating significant new demand hubs.
- Increased adoption of antimicrobial stewardship programs is standardizing antibiotic selection and timing, particularly in critical care and ICU settings.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Asia-Pacific
- Europe
- Rest of World
Segments
- Penicillins
- Cephalosporins
- Carbapenems
- Beta-Lactamase Inhibitor Combinations
- Monobactams